The global dysmenorrhea treatment market, valued at approximately USD 5,937.8 million in 2022, is projected to reach USD 6,324.5 million in 2023 and USD 13,106.5 million by 2032, exhibiting a CAGR of 8.3% over the forecast period 2023-2033. Dysmenorrhea, characterized by severe menstrual cramps, predominantly affects women from adolescence. The pain originates due to prostaglandins produced in the uterine lining, which cause muscular spasms. A variety of underlying conditions may also lead to menstrual problems.
Increasing occurrences of dysmenorrhea due to lifestyle modifications, environmental changes, and dietary preferences have escalated health consciousness among women, driving the demand for treatment options. The rising consumer awareness regarding dysmenorrhea therapies and the affordability of over-the-counter medications further bolster market growth. Moreover, the growing reliance on pain relief drugs during menstruation significantly contributes to market expansion.
Technological advancements within the healthcare sector are anticipated to fuel market growth throughout the forecast period. However, potential side effects associated with long-term treatments, high morbidity of menstrual cramps, inadequate treatments, and traditional family values could impede market progress. Nonetheless, the introduction of portable and advanced DMAs for on-site analysis is expected to enhance global market adoption.
Regionally, North America dominated the market in 2022 with a 37.2% share and is expected to maintain its lead through 2033, driven by technological innovations, increased healthcare spending, and the presence of key industry players. Other regions, particularly Asia-Pacific and EMEA, are anticipated to exhibit significant growth due to rapid industrialization, expanding manufacturing sectors, and substantial investments in research and development within the healthcare industry.
Major market players included in this report are:
Pfizer Inc.
Bayer AG
Johnson & Johnson Services, Inc.
Novartis AG
Abbott Laboratories
Merck & Co., Inc.
Sanofi S.A.
GlaxoSmithKline plc
Mylan N.V.
Teva Pharmaceutical Industries Ltd.
Zydus Cadila
Boehringer Ingelheim International GmbH
Ferring Pharmaceuticals
Endo Pharmaceuticals Inc.
Allergan plc
The detailed segments and sub-segment of the market are explained below:
By Diseases:
Primary Dysmenorrhea
Secondary Dysmenorrhea
Endometriosis
Adenomyosis
Uterine Myomas
Endometrial Polyps
Cervical Stenosis
Obstructive Malformations of Genital Tract
By Therapeutic Class:
Non-Hormonal Medical Treatment
Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
Non-Selective NSAIDS
Cox-2 Inhibitors
Transdermal Glyceryl Trinitrate
Over-The-Counter (OTC) Medications
Hormonal Medicine Treatment
Combined Oral Contraceptive
Progestin Regimens
Levonorgestrel Intrauterine System (LN-IUS)
Surgical Options
Laparoscopy
Hysterectomy
Presacral Neurectomy
Laparoscopic Uterosacral Nerve Ablation (LUNA)
Intrauterine Device (IUD)
Common content for 'Report Description'
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Middle East & Africa
Saudi Arabia
South Africa
RoMEA
Years considered for the study are as follows:
Historical year - 2022
Base year - 2023
Forecast period - 2024 to 2032
Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.
